ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jan 2019
Last Updated on 01 Jul 2022
A- A+
Vedolizumab for treating ulcerative colitis and Crohn’s disease Guidance is outdated and has been withdrawn on 1 July 2022.
Please refer to the updated recommendations on Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease here.
Vedolizumab for ulcerative colitis and Crohn’s disease (Withdrawn 1 Jul 2022)